Novel pyrrolo[2,3-f]isoquinoline based MAPKAP-K2 (MK2) inhibitors with potent in vitro and in vivo activity
Revesz, L., Schlapbach, A., Aichholz, R., Feifel, R., Hawtin, S., Heng, R., Hiestand, P., Jahnke, W., Koch, G., Moebitz, H., Scheufler, C., Velcicky, J., Huppertz, C.To be published.